Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in the Treatment of HIV-Infected Patients: Experience with the First 100 Patients from Qatar
Background. To describe our experience with the use of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (EVG/COBI/FTC/TAF) in the treatment of HIV-infected patients in Qatar including both naïve and treatment experienced. We also report the reasons for switching to EVG/COBI/FTC/TAF in tre...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2020/1597839 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566636511494144 |
|---|---|
| author | Hussam Al Soub A. Latif M. Al-khal Deema Alsoub Waleed Awouda |
| author_facet | Hussam Al Soub A. Latif M. Al-khal Deema Alsoub Waleed Awouda |
| author_sort | Hussam Al Soub |
| collection | DOAJ |
| description | Background. To describe our experience with the use of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (EVG/COBI/FTC/TAF) in the treatment of HIV-infected patients in Qatar including both naïve and treatment experienced. We also report the reasons for switching to EVG/COBI/FTC/TAF in treatment-experienced patients, response to treatment, and tolerability. Method. Review of the medical records of the first 100 HIV-infected patients treated with EVG/COBI/FTC/TAF. Results. Among the 100 HIV-infected patients who were treated with EVG/COBI/FTC/TAF, 64 were Qatari and the rest were from other nationalities. 80 patients were males and 20 were females. 29 were treatment naïve, and 71 were treatment experienced. Among treatment-experienced patients, the most common reasons for switch to EVG/COBI/FTC/TAF were safety concerns, followed by regimen simplification and adverse drug reaction of the previous regimen (40%, 14%, and 13%, respectively). Treatment response to EVG/COBI/FTC/TAF leading to undetectable viral load in naïve patients was 69%, and in treatment-experienced patients, it was 83% with an overall response among all patients of 79%. Excluding those who left the country and whose data were not available, the response rate will be 86%. Tolerability was excellent with mild side effects and no discontinuation due to side effects. Conclusion. Experience with the use of EVG/COBI/FTC/TAF in 100 patients with HIV infection in Qatar was favourable both in treatment naïve patients and in those who were treatment experienced with an excellent tolerability. |
| format | Article |
| id | doaj-art-bdff1708eef54e9c9cb39d2c34dc7937 |
| institution | Kabale University |
| issn | 1712-9532 1918-1493 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases and Medical Microbiology |
| spelling | doaj-art-bdff1708eef54e9c9cb39d2c34dc79372025-02-03T01:03:40ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95321918-14932020-01-01202010.1155/2020/15978391597839Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in the Treatment of HIV-Infected Patients: Experience with the First 100 Patients from QatarHussam Al Soub0A. Latif M. Al-khal1Deema Alsoub2Waleed Awouda3Department of Medicine, Infectious Diseases Division, Hamad Medical Corporation, Doha, QatarDepartment of Medicine, Infectious Diseases Division, Hamad Medical Corporation, Doha, QatarDepartment of Medicine, Infectious Diseases Division, Hamad Medical Corporation, Doha, QatarDepartment of Medicine, Infectious Diseases Division, Hamad Medical Corporation, Doha, QatarBackground. To describe our experience with the use of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (EVG/COBI/FTC/TAF) in the treatment of HIV-infected patients in Qatar including both naïve and treatment experienced. We also report the reasons for switching to EVG/COBI/FTC/TAF in treatment-experienced patients, response to treatment, and tolerability. Method. Review of the medical records of the first 100 HIV-infected patients treated with EVG/COBI/FTC/TAF. Results. Among the 100 HIV-infected patients who were treated with EVG/COBI/FTC/TAF, 64 were Qatari and the rest were from other nationalities. 80 patients were males and 20 were females. 29 were treatment naïve, and 71 were treatment experienced. Among treatment-experienced patients, the most common reasons for switch to EVG/COBI/FTC/TAF were safety concerns, followed by regimen simplification and adverse drug reaction of the previous regimen (40%, 14%, and 13%, respectively). Treatment response to EVG/COBI/FTC/TAF leading to undetectable viral load in naïve patients was 69%, and in treatment-experienced patients, it was 83% with an overall response among all patients of 79%. Excluding those who left the country and whose data were not available, the response rate will be 86%. Tolerability was excellent with mild side effects and no discontinuation due to side effects. Conclusion. Experience with the use of EVG/COBI/FTC/TAF in 100 patients with HIV infection in Qatar was favourable both in treatment naïve patients and in those who were treatment experienced with an excellent tolerability.http://dx.doi.org/10.1155/2020/1597839 |
| spellingShingle | Hussam Al Soub A. Latif M. Al-khal Deema Alsoub Waleed Awouda Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in the Treatment of HIV-Infected Patients: Experience with the First 100 Patients from Qatar Canadian Journal of Infectious Diseases and Medical Microbiology |
| title | Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in the Treatment of HIV-Infected Patients: Experience with the First 100 Patients from Qatar |
| title_full | Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in the Treatment of HIV-Infected Patients: Experience with the First 100 Patients from Qatar |
| title_fullStr | Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in the Treatment of HIV-Infected Patients: Experience with the First 100 Patients from Qatar |
| title_full_unstemmed | Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in the Treatment of HIV-Infected Patients: Experience with the First 100 Patients from Qatar |
| title_short | Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in the Treatment of HIV-Infected Patients: Experience with the First 100 Patients from Qatar |
| title_sort | elvitegravir cobicistat emtricitabine tenofovir alafenamide in the treatment of hiv infected patients experience with the first 100 patients from qatar |
| url | http://dx.doi.org/10.1155/2020/1597839 |
| work_keys_str_mv | AT hussamalsoub elvitegravircobicistatemtricitabinetenofoviralafenamideinthetreatmentofhivinfectedpatientsexperiencewiththefirst100patientsfromqatar AT alatifmalkhal elvitegravircobicistatemtricitabinetenofoviralafenamideinthetreatmentofhivinfectedpatientsexperiencewiththefirst100patientsfromqatar AT deemaalsoub elvitegravircobicistatemtricitabinetenofoviralafenamideinthetreatmentofhivinfectedpatientsexperiencewiththefirst100patientsfromqatar AT waleedawouda elvitegravircobicistatemtricitabinetenofoviralafenamideinthetreatmentofhivinfectedpatientsexperiencewiththefirst100patientsfromqatar |